Sling Therapeutics Company Profile

Background

Sling Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for thyroid eye disease (TED). The company's mission is to enhance patient care by providing convenient, effective therapies that alleviate the burden of current treatment options.

Key Strategic Focus

Sling Therapeutics concentrates on the late-stage development of linsitinib, an oral small molecule inhibitor targeting the insulin-like growth factor I receptor (IGF-1R). This strategic focus aims to offer a non-invasive, patient-friendly alternative to existing TED treatments, addressing a significant unmet need in the market.

Financials and Funding

In June 2022, Sling Therapeutics secured a $35 million Series A financing led by TPG's The Rise Fund. This funding supports the clinical development of linsitinib, including the initiation of Phase 2b and subsequent trials.

Pipeline Development

The company's lead product candidate, linsitinib, has demonstrated promising results in clinical trials:

• Phase 2b/3 LIDS Trial: Completed in January 2025, this trial met its primary endpoint with statistical significance, showing a 52% proptosis responder rate at the 150mg BID dose. Linsitinib was well-tolerated, with no drug-related hearing impairments or significant hyperglycemia reported.

• Confirmatory Phase 3 Trial: Scheduled to commence in 2025, this trial aims to further validate linsitinib's efficacy and safety profile in treating TED.

Technological Platform and Innovation

Linsitinib is a twice-daily oral small molecule that inhibits IGF-1R, a validated target in TED. Its established safety profile, based on treatment of over 900 patients across multiple clinical trials, positions it as a potential first-in-class oral therapy for TED.

Leadership Team

• Ryan Zeidan, Ph.D.: President and Chief Executive Officer. Dr. Zeidan brings extensive experience from roles at Millendo Therapeutics, Celgene, and Novartis, focusing on late-stage assets in rare diseases and oncology.

• Robin Schmidt: Chief Operating Officer. With over 25 years in clinical trial strategy and execution, Ms. Schmidt previously served as Vice President of Clinical Operations at Millendo Therapeutics.

• Catherine Radovich: Vice President of Clinical Operations. Ms. Radovich has over 25 years of experience in clinical trial execution and data delivery, including roles at Millendo Therapeutics and the Michigan Institute for Clinical and Health Research.

• Ronald Dadino: Vice President of CMC and Manufacturing. Mr. Dadino brings over 35 years of experience in pharmaceutical development and manufacturing, with a background in pharmacy and pharmaceutical quality assurance.

• Ken Lock: Chief Commercial Officer. Appointed in June 2025, Mr. Lock has over 20 years of commercial leadership experience, including roles at ACELYRIN, Arcutis Biotherapeutics, Gilead Sciences, Amgen, and Wyeth (now Pfizer).

Leadership Changes

• Raymond Douglas, M.D., Ph.D.: Appointed as Chief Scientific Officer in September 2023. Dr. Douglas is a renowned specialist in thyroid eye disease, bringing extensive clinical and development experience to the team.

• Andrew Guggenhime: Joined the Board of Directors in January 2025. Mr. Guggenhime is an experienced biopharma executive, contributing strategic insights to the company's direction.

Competitor Profile

Market Insights and Dynamics

The TED treatment market is evolving, with a growing emphasis on developing therapies that offer improved efficacy and patient convenience. The introduction of oral small molecule inhibitors like linsitinib represents a significant advancement in this therapeutic area.

Competitor Analysis

• Horizon Therapeutics: Offers Tepezza (teprotumumab), an FDA-approved intravenous therapy for TED. While effective, Tepezza requires a series of infusions, which may be less convenient for patients compared to oral alternatives.

• Immunovant: Developing batoclimab, a subcutaneous anti-FcRn antibody for autoimmune diseases, including TED. This therapy is in earlier stages of development compared to linsitinib.

Strategic Collaborations and Partnerships

Sling Therapeutics in-licensed linsitinib from Astellas Pharma, leveraging existing clinical data to expedite development for TED.

Operational Insights

By focusing on an oral therapy for TED, Sling Therapeutics aims to differentiate itself from competitors offering intravenous or subcutaneous treatments. This approach addresses patient preferences for convenience and may improve adherence to therapy.

Strategic Opportunities and Future Directions

The company plans to initiate a confirmatory Phase 3 trial for linsitinib in 2025, aiming for regulatory approval and commercialization. Additionally, Sling Therapeutics is exploring the potential of linsitinib in other autoimmune and rare diseases, expanding its therapeutic portfolio.

Contact Information

For more information, visit Sling Therapeutics' official website.

Connect with Sling Therapeutics on LinkedIn.

Follow Sling Therapeutics on X (formerly known as Twitter).